{
    "clinical_study": {
        "@rank": "68943", 
        "acronym": "HFPEF", 
        "arm_group": {
            "arm_group_label": "CocoaVia capsules", 
            "arm_group_type": "Experimental", 
            "description": "From baseline to 3 months, patients will consume 2 capsules containing pure epicatechin"
        }, 
        "brief_summary": {
            "textblock": "The major goal of this proposal is to characterize the ability of  epicatechin which a\n      component of dark chocolate to improve the\n\n        1. structural and functional features of skeletal muscle (SkM)\n\n        2. exercise capacity (as assessed by VO2 max)\n\n        3. parameters of diastolic heart function (as assessed by echocardiography)\n\n      We propose that a 3  month treatment with epicatechin (through CocoaVia\u00ae capsules) will lead\n      to a significant improvement in exercise capacity and diastolic function."
        }, 
        "brief_title": "Effects of Epicatechin on Functional Capacity, Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "Patient Inclusion/Exclusion Criteria:\n\n        1. New York Heart Association Class II/III  HF with preserved ejection fraction (EF) of\n           >50%.\n\n        2. Nonsmokers\n\n        3. Subject not taking Coumadin, Xarelto, Prasugrel or Pradaxa. Patients on Plavix for drug\n           eluting stent will not be excluded.\n\n        4. Ages between 40-65. We will exclude any women of child bearing potential"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Medically Diagnosed Heart Failure with Ejection Fraction of >55%\n\n          -  BMI 27-32\n\n          -  No Significant HbA1C fluctuations in past 6 months\n\n        Exclusion Criteria:\n\n          -  Smoking or quit smoking less than 1 year prior to enrollment\n\n          -  Substance Abuse\n\n          -  Taking Coudmadin or Pradaxa"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02068040", 
            "org_study_id": "UCSD IRB 130398"
        }, 
        "intervention": {
            "arm_group_label": "CocoaVia capsules", 
            "description": "CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol", 
            "intervention_name": "CocoaVia", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "Epicatechin consumption"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "with preserved ejection fraction of >55%", 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "contact": {
                "last_name": "Minal Patel", 
                "phone": "858-657-5354"
            }, 
            "facility": {
                "address": {
                    "city": "La Jolla", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92093"
                }, 
                "name": "University of California, San Diego"
            }, 
            "investigator": {
                "last_name": "Pam Taub, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "chocolatestudy2@gmail.com", 
            "last_name": "Minal V Patel", 
            "phone": "858-657-5354"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Objectively evaluate exercise capacity through cycle ergometry to measure VO2 max", 
                "measure": "Change from baseline in exercise capacity", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 3 months"
            }, 
            {
                "description": "The change in skeletal muscle metabolism will be evaluated by magnetic resonance spectroscopy", 
                "measure": "Change from baseline in skeletal muscle metabolism", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 3 months"
            }, 
            {
                "description": "Skeletal muscle biopsies and blood draws will be performed to obtain experimental samples", 
                "measure": "Change from baseline in pre-specified biomarker levels in blood, skeletal muscle, and urine", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 3 months"
            }
        ], 
        "reference": {
            "PMID": "22376256", 
            "citation": "Taub PR, Ramirez-Sanchez I, Ciaraldi TP, Perkins G, Murphy AN, Naviaux R, Hogan M, Maisel AS, Henry RR, Ceballos G, Villarreal F. Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa. Clin Transl Sci. 2012 Feb;5(1):43-7. doi: 10.1111/j.1752-8062.2011.00357.x. Epub 2011 Nov 7."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02068040"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Diego", 
            "investigator_full_name": "Pam Taub, MD", 
            "investigator_title": "Dr. Pam Taub", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of California, San Diego", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of California, San Diego", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}